Principia taps Series A tranche to arm warheads for covalent drug IND

Principia Biopharma will use $12.5 million from the second tranche of a tiered Series A round totaling $36.3 million to file an investigational new drug (IND) application with the US FDA in 2013 for its first covalent drug.